Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.36 USD | +3.13% | +1.65% | -24.96% |
04-23 | Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission | MT |
04-22 | Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.96% | 8B | |
-1.01% | 104B | |
+6.43% | 97.47B | |
+5.71% | 22.25B | |
-12.93% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.19% | 16.36B | |
+8.38% | 14.39B | |
+38.94% | 12.37B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- Legend Biotech Says Phase 3 Trial of Multiple Myeloma Drug Candidate Meets Primary Endpoint; Shares Rise